Extraintestinal manifestations and complications in IBD. (Q38120146)

29 August 2017

Extraintestinal manifestations and complications in IBD. (English)

1 reference

29 August 2017

2

Jürgen Schölmerich

1 reference

29 August 2017

Claudia Ott

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

9 July 2013

1 reference

Nature Reviews Gastroenterology & Hepatology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

10

1 reference

29 August 2017

585-595

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2013.117

29 August 2017

0 references

cites work

Extraintestinal manifestations in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Clinical patterns of familial inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Genetic markers may predict disease behavior in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The joint-gut axis in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Musculoskeletal manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The transition of acute to chronic bowel inflammation in spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Progress in the genetics of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Treatment of extraintestinal manifestations in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Cutaneous manifestations of gastrointestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Important cutaneous manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

21 January 2018

Pyoderma gangraenosum

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Ocular manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pancreatitis in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Hepatobiliary disorders and complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Increased risk of cholelithiasis with prolonged total parenteral nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Therapy insight: Vascular complications in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Thrombosis and inflammatory bowel disease-the role of genetic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pulmonary involvement in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Thoracic manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pulmonary manifestations of inflammatory bowel disease: case presentations and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Renal manifestations and complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Primary chronic interstitial nephritis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Risk factors for developing renal stones in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Urogenital complications of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Tumor necrosis factor-alpha antagonists and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Micronutrient deficiencies in inflammatory bowel disease: from A to zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Reduced bone density in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Low bone mineral density in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Osteoporosis in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

AGA technical review on osteoporosis in gastrointestinal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Musculoskeletal Manifestations in a Population-based Cohort of Inflammatory Bowel Disease Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Extraintestinal manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Extraintestinal manifestations of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Crohn's disease arthritis treated with infliximab: an open trial in four patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Skin manifestations of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pyoderma gangrenosum of the penis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Extraintestinal manifestations of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Primary sclerosing cholangitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Gallbladder hypokinesia in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Hepatosplenic T cell lymphoma in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Drug-induced nephrotoxicity in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Focal white-matter lesions in brain of patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

What is the optimal treatment for anemia in inflammatory bowel disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Metabolic turnover of vitamin B12 in the normal and diseased liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.117

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.

31 March 2020

1 reference

12 December 2020

Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

1 reference

12 December 2020

Renal and urologic complications of inflammatory bowel disease

1 reference

12 December 2020

Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease.

1 reference

12 December 2020

AA amyloidosis: basic knowledge, unmet needs and future treatments

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations.

1 reference

12 December 2020

Variant forms of cholestatic diseases involving small bile ducts in adults

1 reference

12 December 2020

Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease.

1 reference

12 December 2020

Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD.

1 reference

12 December 2020

Adalimumab therapy for recalcitrant pyoderma gangrenosum

1 reference

12 December 2020

Extraintestinal manifestations and complications in inflammatory bowel diseases

1 reference

12 December 2020

The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects.

1 reference

12 December 2020

Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life.

1 reference

12 December 2020

National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications

1 reference

12 December 2020

Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study).

1 reference

12 December 2020

Treatment of ankylosing spondylitis.

1 reference

12 December 2020

10.1038/NRGASTRO.2013.117

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1022103580

0 references

Fatcat ID

release_ynzsaylrk5g5bm3xcdrvbtcx3e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ynzsaylrk5g5bm3xcdrvbtcx3e

24 November 2022

mapped directly with Wikidata item

1 reference